Pilot Study of Hemoglobin Based Oxygen Therapeutics in Elective Coronary Revascularization

Inclusion Criteria: Written informed consent provided before initiation of any study-related procedure, and before any pre-procedural sedation, and agreement to comply with all protocol-specified procedures Acute Coronary Syndrome (Stable and unstable angina or non ST segment Elevation Myocardial Infarction (UA/non-STEMI) [Braunwald class I-III Class B], Appendix 1). Single vessel disease of the Left Coronary Artery (LCA) One vessel disease of the Right Coronary Artery (RCA) Have a single de novo lesion Older than 18 years and younger than 75 years of age Eligible to undergo PCI on the target vessel Exclusion Criteria: Previous Q-wave myocardial infarction Congestive heart failure with Left ventricular Ejection Fraction <35% Confirmed pregnancy Anemia to a hemoglobin level <8.5g/dl Systemic mastocytosis History of known haemorrhagic stroke at any time or any stroke less than or equal to 30 days prior to randomization Severe hypertension (>180/110mmHG) not adequately controlled by antihypertensive therapy at time of study entry Need for mechanical ventilation Renal impairment: Creatinine > 1.6mg/dl Known history of COPD with FEV 1s < 1.0 liter Contra-indications to the use of adenosine, i.e.History of bronchospasm and/or ongoing therapy with theophylline derivatives, >1 degree atrioventricular block in the absence of a functioning electronic pacemaker and treatment with dipyridamole within the prior 24 hours Patients with significant hemodynamic compromise and/or cardiogenic shock requiring inotropic or pressor support or pulmonary edema History of or clinical documentation of severe aortic/mitral valve stenosis, significant aortic valve insufficiency Participation in another trial with an investigational drug or device (of other investigations) including the follow-up period, within the last 30 days before enrollment Inability or unwillingness to perform 30 day follow up Concomitant disease that interferes with prognosis (life expectancy of less than or equal to 6 months Contra-indications to standard drugs for coronary intervention and coronary heart disease: aspirin, heparin, low molecular weight heparin, clopidogrel, contrast dye Patient weight > 110kg